Adial Pharmaceuticals (ADIL) Shares Outstanding (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Shares Outstanding (Entity) of $1.5 million for Q1 2026, up 125.72% sequentially from $668630.0 in Q4 2025, and up 467.4% YoY from $265984.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Shares Outstanding (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Shares Outstanding (Entity) for 10 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 467.4% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 467.4% YoY) and the FY2025 annual result came in at $668630.0, up 244.55% from the prior year.
- Shares Outstanding (Entity) rose to $1.5 million in Q1 2026 per ADIL's latest filing, from $668630.0 in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.5 million in Q1 2026 and troughed at $37950.0 in Q1 2022.
- A 5-year average of $290361.3 and a median of $118157.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) grew 13.39% in 2023, then soared 467.4% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $42700.0 in 2022, then jumped by 55.82% to $66537.0 in 2023, then surged by 191.66% to $194059.0 in 2024, then soared by 244.55% to $668630.0 in 2025, then soared by 125.72% to $1.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.5 million, $668630.0, and $953455.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 4.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 668,630.00 |
| Sep 30, 2025 | 886,852.00 |
| Jun 30, 2025 | 424,909.00 |
| Mar 31, 2025 | 261,590.00 |
| Dec 31, 2024 | 194,059.00 |
| Sep 30, 2024 | 233,427.00 |
| Jun 30, 2024 | 167,310.00 |
| Mar 31, 2024 | 118,157.00 |
| Dec 31, 2023 | 56,986.00 |
| Sep 30, 2023 | 47,141.00 |
| Jun 30, 2023 | 45,257.00 |
| Mar 31, 2023 | 42,342.00 |
| Dec 31, 2022 | 40,060.00 |
| Sep 30, 2022 | 41,159.00 |
| Jun 30, 2022 | 38,906.00 |
| Mar 31, 2022 | 37,042.00 |
| Dec 31, 2021 | 29,742.00 |
| Sep 30, 2021 | 31,757.00 |
| Jun 30, 2021 | 28,142.00 |